Victory Capital Management
CARM

Victory Capital Management’s Carisma Therapeutics CARM Stock Holding History

Victory Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,121
Closed -$13.7K – 2603
2022
Q4 		$13.7K Hold
1,121
– – ﹤0.01% 2530
2022
Q3 		$10K Sell
1,121
-196
-15% -$2.67K ﹤0.01% 2659
2022
Q2 		$21K Sell
1,317
-9
-0.7% -$103 ﹤0.01% 2612
2022
Q1 		$10K Sell
1,326
-52
-4% -$726 ﹤0.01% 2680
2021
Q4 		$22K Sell
1,378
-19
-1% -$382 ﹤0.01% 2689
2021
Q3 		$22K Buy
1,397
+114
+9% +$5.47K ﹤0.01% 2725
2021
Q2 		$119K Buy
1,283
+75
+6% +$4.78K ﹤0.01% 2582
2021
Q1 		$63K Buy
1,208
+200
+20% +$9.44K ﹤0.01% 2648
2020
Q4 		$27K Buy
1,008
+151
+18% +$3.83K ﹤0.01% 2490
2020
Q3 		$24K Buy
857
+3
+0.4% +$60 ﹤0.01% 2428
2020
Q2 		$12K Sell
854
-814
-49% -$11K ﹤0.01% 2466
2020
Q1 		$18K Buy
+1,668
New +$27.3K ﹤0.01% 3124
2019
Q4 		– Sell
-866
Closed -$20K – 2732
2019
Q3 		$20K Buy
+866
New +$20.3K ﹤0.01% 3037

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management's CARM Position: Q1 2023 in Review

Victory Capital Management sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 1,121 shares — an estimated $13.7K sold.

Victory Capital Management first reported a position in CARM in Q3 2019 and held it in 13 quarters. The position peaked at $119K in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • Victory Capital Management reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Victory Capital Management sold 1,121 Carisma Therapeutics shares in Q1 2023, an estimated $13.7K.
  • Victory Capital Management first reported a position in Carisma Therapeutics in Q3 2019 and held it in 13 quarters.
  • Victory Capital Management's Carisma Therapeutics position peaked at $119K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.